SEARCH:   Advanced

Blood, 15 October 2008, Vol. 112, No. 8, pp. 3036-3047. Prepublished online as a Blood First Edition Paper on June 26, 2008; DOI 10.1182/blood-2007-10-118372. This Article Full Text Full Text (PDF) All Versions of this Article: blood-2007-10-118372v1 112/8/3036    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via CrossRef Google Scholar Articles by Gajewski, J. L. Articles by Klumpp, T. R. PubMed PubMed Citation Articles by Gajewski, J. L. Articles by Klumpp, T. R. Related Collections Transfusion Medicine Transplantation Review Articles Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  REVIEW ARTICLES A review of transfusion practice before, during, and after hematopoietic progenitor cell transplantation James L. Gajewski1,2, Viviana V. Johnson3,4, S. Gerald Sandler4, Antoine Sayegh5, and Thomas R. Klumpp1 1 Department of Medicine, Temple University, Philadelphia, PA; 2 Center for Hematologic Malignancies, Oregon Health & Science University, Portland; 3 Department of Pathology and Laboratory Medicine, National Naval Medical Center, Bethesda, MD; 4 Department of Pathology, Georgetown University Hospital, Washington, DC; and 5 Sutter Medical Center, Sacramento, CA The increased use of hematopoietic progenitor cell (HPC) transplantation has implications and consequences for transfusion services: not only in hospitals where HPC transplantations are performed, but also in hospitals that do not perform HPC transplantations but manage patients before or after transplantation. Candidates for HPC transplantation have specific and specialized transfusion requirements before, during, and after transplantation that are necessary to avert the adverse consequences of alloimmunization to human leukocyte antigens, immunohematologic consequences of ABO-mismatched transplantations, or immunosuppression. Decisions concerning blood transfusions during any of these times may compromise the outcome of an otherwise successful transplantation. Years after an HPC transplantation, and even during clinical remission, recipients may continue to be immunosuppressed and may have critically important, special transfusion requirements. Without a thorough understanding of these special requirements, provision of compatible blood components may be delayed and often urgent transfusion needs prohibit appropriate consultation with the patient's transplantation specialist. To optimize the relevance of issues and communication between clinical hematologists, transplantation physicians, and transfusion medicine physicians, the data and opinions presented in this review are organized by sequence of patient presentation, namely, before, during, and after transplantation. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

	Copyright © 2008 by American Society of Hematology         Online ISSN: 1528-0020